New Blood Coagulation Factor XIIa Inhibitors: Molecular Modeling, Synthesis, and Experimental Confirmation.

Anna Tashchilova, Nadezhda Podoplelova, Alexey Sulimov, Danil Kutov, Ivan Ilin, Mikhail Panteleev, Khidmet Shikhaliev, Svetlana Medvedeva, Nadezhda Novichikhina, Andrey Potapov, Vladimir Sulimov

Molecules (Basel, Switzerland) 2022 Feb 12

filter terms:

In the modern world, complications caused by disorders in the blood coagulation system are found in almost all areas of medicine. Thus, the development of new, more advanced drugs that can prevent pathological conditions without disrupting normal hemostasis is an urgent task. The blood coagulation factor XIIa is one of the most promising therapeutic targets for the development of anticoagulants based on its inhibitors. The initial stage of drug development is directly related to computational methods of searching for a lead compound. In this study, docking followed by quantum chemical calculations was used to search for noncovalent low-molecular-weight factor XIIa inhibitors in a focused library of druglike compounds. As a result of the study, four low-molecular-weight compounds were experimentally confirmed as factor XIIa inhibitors. Selectivity testing revealed that two of the identified factor XIIa inhibitors were selective over the coagulation factors Xa and XIa.

Citation

Anna Tashchilova, Nadezhda Podoplelova, Alexey Sulimov, Danil Kutov, Ivan Ilin, Mikhail Panteleev, Khidmet Shikhaliev, Svetlana Medvedeva, Nadezhda Novichikhina, Andrey Potapov, Vladimir Sulimov. New Blood Coagulation Factor XIIa Inhibitors: Molecular Modeling, Synthesis, and Experimental Confirmation. Molecules (Basel, Switzerland). 2022 Feb 12;27(4)